 To VERIFY the confidence from real world experience | |
| 協辦單位 | 高雄市立岡山醫院（委託秀傳醫療社團法人經營） |
| 上課日期時間 | 109年7月17日（星期五）12:30~14:30 【原為2月7日舉辦】 |
| 上課地點 | 高雄市立岡山醫院（委託秀傳醫療社團法人經營） |
| 報名截止日期 | 2020/07/03 |
| 講師 | 賴嘉緯／尊德診所 |
| 課程大綱 | There is debate about the optimum early pharmacological treatment of diabetes, although most authorities recommend metformin. Beyond metformin it is usual to add a second therapy, but often this intensification occurs late, long after good glycaemic control is lost 2. Second line agents include dipeptidyl peptidase?4 (DPP?4) inhibitors, which are good candidates for early combination therapy. DPP?4 inhibitors improve glucose homeostasis synergistically with metformin even in mild hyperglycaemia, without the adverse effects of weight gain and hypoglycaemia.VERIFY (Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of Type 2 diabetes) is an ongoing, 5?year, multinational, multi?ethnic study being conducted in 254 centres across 34 countries (Appendix: Table A1). We aimed to investigate, for the first time, the long?term benefits of early treatment intensification with a DPP?4 inhibitor (vildagliptin)?metformin combination over standard?of?care metformin monotherapy in maintaining durable glycaemic control in people with newly diagnosed Type 2 diabetes. |
| 積分 | 西醫師繼續教育積分、護理師／士積分 |